Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies
Virginia Kaklamani, MD, DSc, explores strategies for mitigating fatigue, nausea, vomiting, and other toxicities and adverse events that may arise when patients receive endocrine therapy in combination with CDK4/6 inhibitors.
EP: 1.A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection
EP: 2.EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection
EP: 3.Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
